Physician Payments Sunshine Act Reintroduced for 2009 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Physician Payments Sunshine Act Reintroduced for 2009


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (Jan. 22)—Senators Chuck Grassley (R-IA) and Herb Kohl (D-WI) introduced S. 301, known as the Physician Payments Sunshine Act of 2009 to the 111th Congress. The legislation requires drug, device, and medical-supply manufacturers that receive payments through Medicare, Medicaid, or the State Children's Health Insurance Program (SCHIP) to disclose to the US Department of Health and Human Services (HHS) any things of value they give to doctors. Items include payments, gifts, travel compensation, honoraria, and funding for continuing education and research. Companies would be required to report these items beginning Mar. 31, 2011.

The bill also requires HHS to establish procedures for companies to submit the required information and procedures for HHS to make this information available online by Sept. 20, 2011.

The bill amends title XI of the Social Security Act “to provide transparency in the relationship between physicians and manufacturers of drugs, devices, biologicals.” The bill is similar to S. 2029,  which is the 2008 version that was introduced to the 110th Congress but never acted upon. The 2009 legislation clarifies the preemption provisions that were questioned in the previous version. The new bill specifies that states have the authority to collect additional information from companies as long as the information is not specifically covered by federal law.

The bill has been referred to the Senate Committee on Finance.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here